<DOC>
	<DOCNO>NCT01128543</DOCNO>
	<brief_summary>This Multicenter , Open-Label , Phase II Study lapatinib Combination Vinorelbine woman document evidence HER2/neu positive breast cancer metastatic recurrent without prior chemotherapy anti-HER2/neu target therapy metastatic relaps set .</brief_summary>
	<brief_title>Lapatinib Combination With Vinorelbine</brief_title>
	<detailed_description>This Multicenter , Open-Label , Phase II Study lapatinib Combination Vinorelbine woman document evidence HER2/neu positive breast cancer metastatic recurrent without prior chemotherapy anti-HER2/neu target therapy metastatic relaps set . Patients receive 1250mg lapatinib day vinorelbine 25mg/sqm IV Day 1and Day 8 , every 3 week 24 week . The study treatment continue patient experience disease progression unacceptable toxicity . The primary objective study objective response rate ( ORR , define CR + PR ) toxicity . Secondary objective include DFS , duration response .</detailed_description>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Histologically confirm adenocarcinoma breast . Patients must &gt; 18 year age Metastatic breast cancer ( stage IV ) primary diagnosis relapse curative intent therapy . Laboratory confirm HER2/neu overexpressing and/or amplify disease invasive component primary metastatic lesion Patients must evidence metastatic disease , measurable disease mandatory . The patient may receive prior treatment chemotherapeutic agent include taxanes , trastuzumab anthracycline adjuvant metastatic setting permit . Prior treatment radiation therapy adjuvant and/or metastatic setting permit provide least 4 week elapse since last fraction radiation therapy treatment related adverse event &lt; grade 1 time enrollment . Prior radiation solitary metastatic lesion permit provided progression post radiation document . Patients must life expectancy &gt; 3 month . ECOG performance status 0 , 1 2 ( see Appendix II ) . Patients must normal organ marrow function measure within 14 day prior enrollment define Table 1 . Left ventricular ejection fraction &gt; 50 % demonstrate MUGA scan/echocardiogram within 4 week prior enrollment . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 7 day prior enrollment must use acceptable method contraception duration study . Female patient lactate discontinue nursing prior first dose investigational product refrain nursing throughout treatment period 14 day follow last dose investigational product . The patient must sign consent form prior enrollment . Patients must accessible treatment followup . Patients history malignancy , except : adequately treat DCIS , adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumour ( nonbreast ) curatively treat evidence disease &gt; 5 year . Patients receive ongoing anticancer treatment investigational anticancer agent breast cancer patient use investigational drug within 30 day 5 halflives ( know ) , whichever longer , precede date enrollment . Patients symptomatic CNS metastasis ( include leptomeningeal involvement ) . Patients bone metastasis . Patients serious cardiac illness condition include , limited : history document congestive heart failure ( CHF ) systolic dysfunction ( LVEF &lt; 50 % ) high risk uncontrolled arrhythmia ( ventricular tachycardia , highgrade AVblock , supraventricular arrhythmia adequately ratecontrolled ) unstable angina pectoris require antianginal medication clinically significant valvular heart disease evidence transmural infarction ECG inadequately control hypertension ( systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 100 mmHg ) . New York Heart Association ( NYHA ) Class III IV functional status ( see Appendix X ) Patients receive vinorelbine prior therapy metastatic recurrent set . Patients serious illness medical condition would permit patient manage accord protocol include , limited : History significant neurologic psychiatric disorder would impair ability obtain consent limit compliance study requirement . Active uncontrolled infection . Serious nonhealing wound , ulcer , bone fracture . Patients GI tract disease result inability take oral medication limit malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption ( example resection stomach small bowel ) uncontrolled inflammatory GI disease ( e.g . Crohn 's , ulcerative colitis ) . Patients receive CYP3A4 inhibitor inducer eligible unless &gt; 7 &gt; 14 day , respectively since last dose medication start protocol treatment ( see Appendix IX ) . For amiodarone particular , dose prohibit least 6 month prior start protocol treatment . Patients history allergic hypersensitivity reaction study drug excipients history allergic reaction attribute compound similar chemical composition study drug . Pregnant lactation woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>lapatinib</keyword>
	<keyword>breast cancer</keyword>
</DOC>